Initial Therapy at Academic Centers Linked to Prolonged Overall Survival in NSCLC

Share this content:
Patients diagnosed with NSCLC between 2010 and 2013 had a median OS of 14.8 months compared with 12.4 months among patients diagnosed between 2004 and 2009.
Patients diagnosed with NSCLC between 2010 and 2013 had a median OS of 14.8 months compared with 12.4 months among patients diagnosed between 2004 and 2009.
The following article features coverage from the IASLC 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. Click here to read more of Cancer Therapy Advisor's conference coverage.

Overall survival with non–small cell lung cancer (NSCLC) may be improved by initial treatment at an academic center rather than a non-academic facility, according an oral abstract presented at the International Association for the Study of Lung Cancer (IASLC) 18th Annual World Conference on Lung Cancer in Japan.1

Researchers accessed and compiled the data from the National Cancer Database (NCDB) of 1,150,722 patients with NSCLC and separated them into 2 arms by receipt of initial treatment at an academic center (31.5%) and from a non-academic center (68.5%). Several baseline characteristics were different between the 2 groups, including age, race, comorbidity score, cancer stage, median income, course of treatment, and distance from treatment center.

Median overall survival (OS) for patients in all cohorts was 13.1 months, though OS improved significantly over time. Patients diagnosed with NSCLC in 2010 to 2013 had a median OS of 14.8 months compared with 12.4 months in patients diagnosed in 2004 to 2009 (P < .001).

Patients treated at academic centers also had a lower risk of death (hazard ratio [HR], 0.91; 95% CI, 0.906-0.919; P < .001); 4-year OS rates were 25% and 19% among patients treated at academic and non-academic centers, respectively (P < .001).

The authors concluded that “factors influencing treatment facility choice should be addressed for easier access to academic centers.”

Read more of Cancer Therapy Advisor's coverage of the IASLC 18th World Conference on Lung Cancer (WCLC) by visiting the conference page.

Reference

  1. Dholaria B, Ailawadhi S, Soyano AE, et al. Survival trends among non-small cell lung cancer (NSCLC) patients over a decade: impact of initial therapy at academic centers. Presented at: International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer; October 2017; Yokohama, Japan. Abstract OA 06.07.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs